Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Pazopanib showed no clear difference in progression‐free survival (absolute effect size estimates based on… compared with sunitinib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Pazopanib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with sunitinib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
Progression‐free survival · Previous treated and treatment‐naïve (54%) metastatic renal cell carcinoma (clear cell type)
Pazopanib leads to lower progression‐free survival (absolute effect size estimates based on… compared with placebo (targeted agent versus placebo) (high certainty).
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Pazopanib showed no clear difference in serious adverse events (Grade 3 or 4) compared with sunitinib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 24 months) · Previous treated and treatment‐naïve (54%) metastatic renal cell carcinoma (clear cell type)
Pazopanib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with placebo (targeted agent versus placebo) (low certainty).
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Previous treated and treatment‐naïve (54%) metastatic renal cell carcinoma (clear cell type)
Pazopanib leads to higher serious adverse events (Grade 3 or 4) compared with placebo (targeted agent versus placebo) (high certainty).
1 finding from 1 review
Health‐related quality of life · Previous treated and treatment‐naïve (54%) metastatic renal cell carcinoma (clear cell type)
1 finding from 1 review
Health‐related quality of life (mean change value) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
1 finding from 1 review
Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Tivozanib may leads to lower progression‐free survival (absolute effect size estimates based on… compared with sorafenib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
Intervention not reported
Number of patients with all vascular events (stroke, MI, non‐fatal cardiac arrest, unstable angina requiring revascularisation, vascular death) at 90 days and at 1 year · patients with TIA or ischaemic stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Number of patients with safety events (total AEs, infections, SAEs) · patients with TIA or ischaemic stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Number of patients with recurrent stroke (fatal and non‐fatal) at 90 days and at 1 year · patients with TIA or ischaemic stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Number of patients with all‐cause death · patients with TIA or ischaemic stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Number of patients with cardiovascular death · patients with TIA or ischaemic stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Number of patients with infection · patients with TIA or ischaemic stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Number of patients with non‐scheduled hospitalisation · patients with TIA or ischaemic stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Remission of primary anxiety diagnosis post‐treatment (ITT) · children and adolescents with anxiety disorders
CBT probably leads to higher remission of primary anxiety diagnosis post‐treatment (ITT) compared with waitlist (moderate certainty).
1 finding from 1 review
Acceptability (number of participants lost to post‐treatment assessment) · children and adolescents with anxiety disorders
CBT showed no clear difference in acceptability (number of participants lost to post‐treatment… compared with treatment (low certainty).
1 finding from 1 review
Remission of all anxiety diagnoses post‐treatment (ITT) · children and adolescents with anxiety disorders
CBT may leads to higher remission of all anxiety diagnoses post‐treatment (ITT) compared with treatment (low certainty).
1 finding from 1 review
Anxiety · children and adolescents with anxiety disorders
1 finding from 1 review